Discovery of Novel Boronates; Structural Building Blocks of Potential Enzyme Inhibitors
Document Type
Poster
Event Website
https://source2022.sched.com/
Start Date
16-5-2022
End Date
16-5-2022
Keywords
Boron, Medicine, Chemistry
Abstract
As bacteria and viruses continue to mutate and develop multidrug resistance, the urgency for developing more effective treatments increases. While this increase in mutation can be somewhat mitigated by the modification of current medicinal treatments, more long-term solutions involve the use of more novel remedies. Past investigations with the use of boron-containing compounds have shown significant potential as potent therapeutic compounds. Currently, there are five boron-containing FDA-approved medications. This supports the potential effectiveness of boron-containing chemical compounds and it indicates the need for more in-depth research, discovery, and development. Currently, the Fabry research group focuses its efforts on the synthesis of boron-modified inhibitors of HIV-1 aspartic protease. This work involves a homologation reaction followed by a nucleophilic bimolecular substitution. The obtained novel boronates are characterized using nuclear magnetic resonance (NMR) spectroscopy and gas chromatography/mass spectrometry (GC/MS). The ultimate goal of this project is to create a diverse library of novel boron compounds and to test the limits of synthetic boron chemistry.
Recommended Citation
Ditter, Kaitlyn; Pratt, Tyler; and Reynolds, Hannah, "Discovery of Novel Boronates; Structural Building Blocks of Potential Enzyme Inhibitors" (2022). Symposium Of University Research and Creative Expression (SOURCE). 38.
https://digitalcommons.cwu.edu/source/2022/COTS/38
Department/Program
Biological Sciences
Additional Mentoring Department
Chemistry
Additional Mentoring Department
Funding from Central OUR Grants
Poster
Discovery of Novel Boronates; Structural Building Blocks of Potential Enzyme Inhibitors
As bacteria and viruses continue to mutate and develop multidrug resistance, the urgency for developing more effective treatments increases. While this increase in mutation can be somewhat mitigated by the modification of current medicinal treatments, more long-term solutions involve the use of more novel remedies. Past investigations with the use of boron-containing compounds have shown significant potential as potent therapeutic compounds. Currently, there are five boron-containing FDA-approved medications. This supports the potential effectiveness of boron-containing chemical compounds and it indicates the need for more in-depth research, discovery, and development. Currently, the Fabry research group focuses its efforts on the synthesis of boron-modified inhibitors of HIV-1 aspartic protease. This work involves a homologation reaction followed by a nucleophilic bimolecular substitution. The obtained novel boronates are characterized using nuclear magnetic resonance (NMR) spectroscopy and gas chromatography/mass spectrometry (GC/MS). The ultimate goal of this project is to create a diverse library of novel boron compounds and to test the limits of synthetic boron chemistry.
https://digitalcommons.cwu.edu/source/2022/COTS/38
Faculty Mentor(s)
Levente Fabry-Asztalos